Trials / Recruiting
RecruitingNCT07154134
Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 28 Weeks – 36 Weeks
- Healthy volunteers
- Not accepted
Summary
This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.
Detailed description
Preterm birth continues to be one of the significant challenges in perinatal medicine because of its high incidence of morbidities and mortalities. Its burden on the infant, the family, healthcare systems, and society is enormous. Endocan is implicated in the recruitment of circulating lymphocytes to inflammatory sites and leukocyte adhesion and activation. Endocan also inhibits leukocyte-endothelial cell adhesion and reduces the excessive leukocyte recruitment into the lungs. Copeptin, also known as the arginine vasopressin (AVP) associated glycopeptides. AVP is a vasoactive neurohypophysial hormone. It is one of the primary hormones of the hypothalamic-pituitary-adrenal axis, and its primary function is to regulate water and maintain electrolyte homeostasis. The primary stimulus for AVP release is hyperosmolarity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Serum endocan | Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life. |
| DIAGNOSTIC_TEST | Serum copeptin | Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life. |
Timeline
- Start date
- 2025-07-10
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2025-09-04
- Last updated
- 2025-09-04
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07154134. Inclusion in this directory is not an endorsement.